已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

医学 苯达莫司汀 美罗华 套细胞淋巴瘤 长春新碱 内科学 切碎 强的松 临床终点 外科 胃肠病学 环磷酰胺 淋巴瘤 化疗 随机对照试验
作者
Mathias Rummel,N. Niederle,Georg Maschmeyer,Gamal-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Balló,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger
出处
期刊:The Lancet [Elsevier]
卷期号:381 (9873): 1203-1210 被引量:1317
标识
DOI:10.1016/s0140-6736(12)61763-2
摘要

Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. Bendamustine plus rituximab is effective for relapsed or refractory disease. We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. Methods We did a prospective, multicentre, randomised, open-label, non-inferiority trial at 81 centres in Germany between Sept 1, 2003, and Aug 31, 2008. Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. Patients were stratified by histological lymphoma subtype, then randomly assigned according to a prespecified randomisation list to receive either intravenous bendamustine (90 mg/m2 on days 1 and 2 of a 4-week cycle) or CHOP (cycles every 3 weeks of cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 on day 1, and prednisone 100 mg/day for 5 days) for a maximum of six cycles. Patients in both groups received rituximab 375 mg/m2 on day 1 of each cycle. Patients and treating physicians were not masked to treatment allocation. The primary endpoint was progression-free survival, with a non-inferiority margin of 10%. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00991211, and the Federal Institute for Drugs and Medical Devices of Germany, BfArM 4021335. Findings 274 patients were assigned to bendamustine plus rituximab (261 assessed) and 275 to R-CHOP (253 assessed). At median follow-up of 45 months (IQR 25–57), median progression-free survival was significantly longer in the bendamustine plus rituximab group than in the R-CHOP group (69·5 months [26·1 to not yet reached] vs 31·2 months [15·2–65·7]; hazard ratio 0·58, 95% CI 0·44–0·74; p<0·0001). Bendamustine plus rituximab was better tolerated than R-CHOP, with lower rates of alopecia (0 patients vs 245 (100%) of 245 patients who recieved ≥3 cycles; p<0·0001), haematological toxicity (77 [30%] vs 173 [68%]; p<0·0001), infections (96 [37%] vs 127 [50%]); p=0·0025), peripheral neuropathy (18 [7%] vs 73 [29%]; p<0·0001), and stomatitis (16 [6%] vs 47 [19%]; p<0·0001). Erythematous skin reactions were more common in patients in the bendamustine plus rituximab group than in those in the R-CHOP group (42 [16%] vs 23 [9%]; p=0·024). Interpretation In patients with previously untreated indolent lymphoma, bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP because of increased progression-free survival and fewer toxic effects. Funding Roche Pharma AG, Ribosepharm/Mundipharma GmbH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
学术智子完成签到,获得积分10
2秒前
QIQI完成签到,获得积分10
4秒前
zhaojj发布了新的文献求助10
6秒前
hins完成签到,获得积分10
7秒前
钉钉完成签到 ,获得积分10
9秒前
12秒前
QIQI发布了新的文献求助10
12秒前
user_one完成签到,获得积分10
13秒前
王者归来完成签到,获得积分10
13秒前
2568269431完成签到 ,获得积分10
15秒前
慕青应助诚心的自中采纳,获得10
16秒前
Nini1203发布了新的文献求助30
17秒前
Liao完成签到 ,获得积分10
23秒前
老实鞯完成签到 ,获得积分10
24秒前
Misaki发布了新的文献求助10
26秒前
LZL完成签到 ,获得积分10
26秒前
黯然完成签到 ,获得积分10
27秒前
imkhun1021完成签到,获得积分10
27秒前
Misaki完成签到,获得积分10
32秒前
洪东智完成签到,获得积分10
33秒前
压缩完成签到 ,获得积分10
34秒前
充电宝应助yangon采纳,获得10
34秒前
spring完成签到 ,获得积分10
36秒前
儒雅的焦发布了新的文献求助10
36秒前
伊笙完成签到 ,获得积分10
37秒前
locker完成签到 ,获得积分10
38秒前
无畏完成签到,获得积分10
38秒前
40秒前
乐乐完成签到,获得积分10
41秒前
42秒前
Priscilla应助科研通管家采纳,获得10
42秒前
42秒前
Ava应助科研通管家采纳,获得10
42秒前
小马甲应助科研通管家采纳,获得10
42秒前
杳鸢应助科研通管家采纳,获得100
43秒前
ding应助科研通管家采纳,获得10
43秒前
45秒前
zhong发布了新的文献求助10
47秒前
49秒前
49秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162149
求助须知:如何正确求助?哪些是违规求助? 2813236
关于积分的说明 7899361
捐赠科研通 2472473
什么是DOI,文献DOI怎么找? 1316444
科研通“疑难数据库(出版商)”最低求助积分说明 631317
版权声明 602142